A phase II trial of dose-reduced nab-paclitaxel for patients with previously treated, advanced or recurrent gastric cancer (OGSG 1302)

BACKGROUND: For unresectable or recurrent advanced gastric adenocarcinoma (AGC), tri-weekly administration of nanoparticle albumin-bound paclitaxel (nab-PTX) at 260 mg/m(2) achieved a response rate of 27.8% in a phase II trial in Japan. However, frequent neutropenia and peripheral neuropathy limit i...

Descripción completa

Detalles Bibliográficos
Autores principales: Tamura, Shigeyuki, Taniguchi, Hirokazu, Nishikawa, Kazuhiro, Imamura, Hiroshi, Fujita, Junya, Takeno, Atsushi, Matsuyama, Jin, Kimura, Yutaka, Kawada, Junji, Hirao, Motohiro, Hirota, Masashi, Fujitani, Kazumasa, Kurokawa, Yukinori, Sakai, Daisuke, Kawakami, Hisato, Shimokawa, Toshio, Satoh, Taroh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7677284/
https://www.ncbi.nlm.nih.gov/pubmed/32926227
http://dx.doi.org/10.1007/s10147-020-01768-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7677284/
https://www.ncbi.nlm.nih.gov/pubmed/32926227
http://dx.doi.org/10.1007/s10147-020-01768-w

Ejemplares similares